Valiant Laboratories Limited — Important, 10-07-2025: Updates

Valiant Laboratories has announced a board meeting to consider a Rights Issue of fully paid-up equity shares totaling up to ₹81.47 Cr. The Rights Issue aims to raise funds primarily to adjust unsecured loans from promoters (₹58.01 Cr), repay certain outstanding loans (₹1.40 Cr), finance capital expenditure (₹1.80 Cr) related to process plant strengthening and HVAC installation, and support general corporate purposes (up to 25% of proceeds). The company manufactures paracetamol API and the promoters intend to subscribe fully to their rights entitlement without renunciation outside the promoter group. The issue has no minimum subscription requirement and will be listed on BSE and NSE. Financially, Valiant reported a net loss of ₹2.20 Cr in FY25 with declining revenues from ₹182 Cr to ₹133 Cr. Promoters hold over 50% stake, with the board comprising seven directors including three independents.